Results 61 to 70 of about 13,103,023 (178)
Nucleos(t)ide analog therapy blocks DNA synthesis by the hepatitis B virus (HBV) reverse transcriptase and can control the infection, but treatment is life-long and has high costs and unpredictable long-term side effects.
John E Tavis +10 more
doaj +1 more source
Minimal residual viremia in HBeAg negative individuals treated with nucleos(t)ide analogues.
Minimal residual viremia in HBeAg negative individuals treated with nucleos(t)ide analogues.
Melanie Maier (427543) +5 more
core +1 more source
. Hepatitis B virus (HBV) represents the commonest etiologic agent of acute-on-chronic liver failure (ACLF) in most Asian countries. Nucleos(t)ide analogs (NAs) are effective in the treatment of chronic HBV infections, but may also exacerbate the disease
Ying Zheng +19 more
doaj +1 more source
Systematic review and meta-analysis: de novo combination of nucleos(t)ide analogs and pegylated interferon alpha versus pegylated interferon alpha monotherapy for the functional cure of chronic hepatitis B. [PDF]
Introduction: Chronic hepatitis B (CHB) is a worldwide infectious disease caused by hepatitis B virus (HBV). Optimizing antiviral treatment strategies could improve the functional cure (FC) rate of patients with CHB.
Wei N +5 more
europepmc +2 more sources
Background Antiviral therapy should reduce the recurrence of hepatitis B virus‐related hepatocellular carcinoma (HBV‐related HCC) after surgical resection.
Weili Qi +11 more
doaj +1 more source
Dynamics of HBV biomarkers during nucleos(t)ide analog treatment: A 14-year study
Background: Circulating HBsAg, HBV RNA, and hepatitis B core-related antigen (HBcrAg) are potential biomarkers for the response to nucleos(t)ide analog (NA) treatment discontinuation in patients with chronic hepatitis B (CHB).
Florian van Bömmel +11 more
openaire +3 more sources
Virologic Response, Early HIV-1 Decay, and Maraviroc Pharmacokinetics With the Nucleos(t)ide-Free Regimen of MaravIroc Plus Darunavir/Ritonavir in a Pilot Study [PDF]
To address the need for nucleos(t)ide reverse transcriptase inhibitor (NRTI)-sparing regimens, we explored the virologic and pharmacokinetic characteristics of maraviroc plus ritonavir-boosted darunavir in a single-arm, open-label, 96-week ...
Acosta, Edward P +26 more
core +1 more source
Caucasian Ethnicity, but Not Treatment Cessation is Associated with HBsAg Loss Following Nucleos(t)ide Analogue-Induced HBeAg Seroconversion [PDF]
It is well appreciated that ethnicity influences the natural history and immune responses during a chronic hepatitis B infection. In this study, we explore the effect of ethnicity and treatment cessation on Hepatitis B surface Antigen (HBsAg ...
Sersté, T. (Thomas) +12 more
core +2 more sources
Enrichment in amino acid changes related to nucleos(t)ide analog resistance in the pre-treatment quasispecies.
Israel Ortega (161084) +16 more
core +1 more source
Background and Aim Although tenofovir alafenamide (TAF), as well as entecavir (ETV), is widely used as first‐line treatment for patients with chronic hepatitis B, there are only a few studies comparing sequential therapy from ETV to TAF and continuous ...
Norio Itokawa +32 more
doaj +1 more source

